Assembly Biosciences
Carrie Dunn's work experience includes various roles in the pharmaceutical and biotechnology industry. Carrie most recently worked at Assembly Biosciences, Inc. as the Director of GMP QA (QA Operations). Prior to that, they were the Associate Director of GMP QA at the same company. Before joining Assembly Biosciences, Inc., Carrie worked at Karyopharm Therapeutics Inc. as a Senior Manager/Associate Director of GMP QA. Carrie also gained experience in GMP quality assurance at Cubist Pharmaceuticals, where they served as a Manager. Earlier in their career, Carrie worked as a Quality Assurance Professional at Protein Sciences Corporation and as a Clinical Data Associate at Kendle International. Carrie began their career at Amgen, where they held roles as a Project Manager and a Quality Control Cell/Immunobiology Lab Analyst. Carrie also has research experience as a Research Assistant at the University of Massachusetts Dartmouth and as a Consultant at Battelle Ocean Sciences. Carrie has a background in biology and has previously worked as a Biology Laboratory Teaching Assistant and a Math Tutor.
Carrie Dunn graduated from the University of Massachusetts Dartmouth in 1997 with a BS degree in Marine Biology and Biochemistry.
This person is not in any offices
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.